Zobrazeno 1 - 10
of 21
pro vyhledávání: ''
Autor:
Clémentine Sarkozy, Benjamin Suttle, Lionel Karlin, Romain Dubois, Gilles Salles, Sydney Dubois, Fabrice Jardin, Peggy Cullières-Dartigues, Steven Le Gouill, Hervé Tilly, Vincent Ribrag, Franck Morschhauser, Jean-Marie Michot, Jean-Michel Picquenot, Thierry Jo Molina, Charles Herbaux
Publikováno v:
Clinical Cancer Research. 26:3145-3153
Purpose: The histone-methyl transferase EZH2, catalytic subunit of the PRC2 complex involved in transcriptional regulation, is mutated in approximately 25% of germinal center B-cell lymphomas. Aberrant proliferative dependency on EZH2 activity can be
Autor:
Mohammad Azab, Ursula A. Matulonis, H Hirte, Bristi Basu, Susana Banerjee, John Nemunaitis, Harold N. Keer, Benjamin Schwartz, Deborah K. Armstrong, Patricia S. Braly, Merry Jennifer Markham, Rebecca Kristeleit, Lynda D. Roman, Diane Provencher, Daniela Matei, Sue Naim, Geoff Hall, Aram Oganesian, Simone Jueliger, Sarah P. Blagden, Michael J. Birrer, Sharad A. Ghamande, Kenneth P. Nephew, Angeles Alvarez Secord, Amit M. Oza, Yong Hao, William P. McGuire, Gini F. Fleming
Publikováno v:
Clin Cancer Res
Purpose: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadecitabine, a
Autor:
Pamela Heeter, Erika Cavallone, Frank McCormick, Lawrence K. Kaplan, Laura B. Pincus, Wade Berry, Basem M. William, Aaron Zhan, Khoan Vu, Jonathan E. Brammer, Chen-Yen Yang, Charalambos Andreadis, Matthew J. Wieduwilt, Pierluigi Porcu, Weiyun Z. Ai, Chi-Heng Wu
Publikováno v:
Clinical Cancer Research. 26:1000-1008
Purpose: The histone deacetylase (HDAC) inhibitor romidepsin and the anthracycline liposomal doxorubicin (LD) have modest single-agent activity in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). We investigated the safety and
Autor:
Ravi Vij, Mark A. Fiala, Mark A. Schroeder, Savina Jaeger, Keith Stockerl-Goldstein, Armin Ghobadi, Tanya M. Wildes, Kathryn Shea, Eric Huselton, Sae Rin Jean, Michael H. Cardone
Publikováno v:
Clin Cancer Res
Purpose: Pegylated liposomal doxorubicin (PLD) combined with bortezomib is an effective salvage regimen for relapsed refractory multiple myeloma (RRMM). Carfilzomib, a second-generation proteasome inhibitor, has clinical efficacy even among bortezomi
Autor:
David J. Straus, Nancy L. Bartlett, Radhakrishnan Ramchandren, Joseph M. Connors, Keenan Fenton, Andres Forero-Torres, Gerald Engley, Thomas Manley, Ranjana H. Advani, John Kuruvilla, Kerry J. Savage, Jonathan W. Friedberg, Stephen M. Ansell, Leo I. Gordon, Ajay K. Gopal, Anas Younes, Tatyana Feldman, Robert T. Chen
Publikováno v:
Clinical Cancer Research. 25:1718-1726
Purpose: To evaluate safety and efficacy outcomes for subjects on the ECHELON-1 study treated in North America (NA). Patients and Methods: ECHELON-1 is a global, open-label, randomized phase III study comparing doxorubicin, vinblastine, and dacarbazi
Autor:
Katherine M. Bell-McGuinn, George Coukos, Carolyn K. McCourt, Alexander Malykhin, Kristi Manjarrez, Heather A. Lankes, Andrea Facciabene, Robert M. Hershberg, Gwenn Danet-Desnoyers, Joan L. Walker, Carol Aghajanian, Paula M. Fracasso, William E. Brady, Bradley J. Monk
Publikováno v:
Clinical Cancer Research. 23:1955-1966
Purpose: Immunotherapy is an emerging paradigm for the treatment of cancer, but the potential efficacy of many drugs cannot be sufficiently tested in the mouse. We sought to develop a rational combination of motolimod—a novel Toll-like receptor 8 (
Autor:
Gunter von Minckwitz, Bianca Lederer, Bernd Gerber, Jens Huober, Thomas Rüdiger, Jens-Uwe Blohmer, Frederick Klauschen, Stephan Wienert, Sibylle Loibl, Wolfgang D. Schmitt, Erhard Erbstößer, Carsten Denkert, Keyur Mehta, Manfred Dietel
Publikováno v:
Clinical Cancer Research. 21:3651-3657
Purpose: Scoring proliferation through Ki67 immunohistochemistry is an important component in predicting therapy response to chemotherapy in patients with breast cancer. However, recent studies have cast doubt on the reliability of “visual” Ki67
Autor:
David S. Schrump, Seth M. Steinberg, Jane B. Trepel, Ari Frosch, Richard Piekarz, Ariel Lopez-Chavez, Eva Szabo, Barbara Scepura, Yusuke Tomita, Cody J. Peer, Giuseppe Giaccone, Christophe E. Redon, Corey A. Carter, Anish Thomas, Min-Jung Lee, Arun Rajan, William D. Figg, Yuanbin Chen
Publikováno v:
Clinical Cancer Research. 20:5392-5402
Purpose: This phase I/II study sought to determine the safety and maximum tolerated dose (MTD) of a novel schedule of belinostat, a histone deacetylase inhibitor (HDAC) administered before and in combination with cisplatin (P), doxorubicin (A), and c
Autor:
Giampaolo Bianchini, Patricia Gomez, Aleix Prat, Begoña Bermejo, Federico Vazquez, José Baselga, Mikhail Byakhow, Sergei Tjulandin, Milvia Zambetti, Astrid Koehler, Wolfgang Eiermann, L. Gianni, Anton Belousov, Marlene Thomas, Vladimir Semiglazov, Maggie C.U. Cheang
Publikováno v:
Clinical Cancer Research. 20:511-521
Purpose: We report a retrospective exploratory analysis of the association of the research-based prediction analysis of microarray 50 (PAM50) subtype predictor with pathologic complete response (pCR) and event-free survival (EFS) in women enrolled in
Autor:
S.N. Akers, Carl A. Batt, Austin Miller, Junko Matsuzaki, Sacha Gnjatic, Takemasa Tsuji, Gerd Ritter, Amy Beck, Smitha R. James, Adam R. Karpf, Shashikant Lele, Wa Zhang, Paulette Mhawech-Fauceglia, Elizabeth A. Griffiths, Kunle Odunsi, Anthony Miliotto
Publikováno v:
Cancer Immunology Research. 2:37-49
The cancer–testis/cancer germline antigen, NY-ESO-1, is a vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation, we hypothesized that DNA methyltr